Life-Sciences-Europe.com
The European Life Sciences Web Portal

This is a free web portal for the life sciences in Europe and Israel... » read more

BioNTech & Genmab Expand Cancer MAb Strategic Collaboration (2022-08-05)
> Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumors > Expanded collaboration leverages Genmab’s proprietary HexaBody® technology platform to develop novel immunotherapies > First monospecific an...
F2G Ltd: $70m Financing Led by Forbion & Sofinnova Partners (2022-08-04)
New Investment from Forbion and Sofinnova Partners F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening rare fungal infections with a high unmet medical need, today announces ...
Gilead Sciences to Acquire MiroBio for $405m in Cash (2022-08-04)
> Acquisition Provides Gilead with MiroBio’s Pipeline of Immune Checkpoint Agonists and Proprietary Discovery Platform > MiroBio’s Scientific Approach to Restoring Immune Balance for the Treatment of Autoimmune Diseases Complements Gilead’s Inflammation Research...
RoslinCT & Lykan Bioscience Merge to Create Leading CDMO (2022-08-04)
> Combination creates global leader in process development and GMP manufacturing of advanced cell and gene therapies with transatlantic footprint in the US and UK > Key leadership, staff and shareholders of both businesses will remain and have reinvested in the ...
Congenica & GenomOncology: Precision Oncology Solution (2022-08-04)
Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology Solution. Driven ...
Formycon: FDA Approves the First Biosimilar to Lucentis (2022-08-03)
> CIMERLI™ is the only biosimilar approved for all five Lucentis® indications > Commercially available in 0.3 mg and 0.5 mg dosages > U.S. commercial launch by Coherus BioSciences, Inc. expected in early October 2022 Formycon AG (“Formycon”), Polpharma B...
Bio-Rad Acquires Curiosity Diagnostics for up to $170m (2022-08-03)
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope F...
Poseida & Roche: Global Strategic CAR-T Cell Collaboration (2022-08-03)
> Leveraging Poseida's novel approach to cell therapy and Roche's expertise in developing and commercializing therapies to transform cancer care, the collaboration is focused on advancing multiple existing and additional next generation allogeneic CAR-T programs di...
Quantro Therapeutics Collaborates with Boehringer Ingelheim (2022-08-03)
QUANTRO Therapeutics today announced that they have entered a three-year collaboration, option and license agreement with Boehringer Ingelheim for the identification and development of inhibitors for up to three cancer-associated transcription factors. The collabor...
UoM Spin-out Imperagen Raises £3.5m Seed Round (2022-08-03)
Imperagen has developed a unique technology to accelerate the design, optimisation, and validation of novel enzymes for large molecular drug discovery. Northern Gritstone, along with IQ Capital, has led a £3.5 million Seed Round to fund the initial spin out of Impe...

» Show all News!

Life-Sciences-Europe.com is your doorway to the European life sciences!

[LSE] provides free, up-to-date and structured access to

– News
– Products
– Persons
– Organisations
– Financings
– Collaborations

in Europe and Israel.

Access is unrestricted and free, requiring no log in and no user registration.The high-quality content is not related to the advertising, with topical relevance being the criterion for inclusion. [LSE] is 100% Made in Germany!

» Start here with the latest News!

Picture [iito] Fighting Customers 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]